Andrew DudumCo-founder & CEO, Hims & Hers Health, Inc. (HIMS)
3 recorded appearances
Dudum defends the company against the FTC's lawsuit, explains the shift from compounded to branded GLP-1s, and says he expects cash-pay monthly costs to fall to roughly $40-50 from $150-200. He also says Hims is building its own AI infrastructure instead of paying third-party agent vendors.
Recorded after a roughly 66% drawdown in the stock, Dudum argues being public is a net advantage, dismisses the dedicated "strategy" hire, contends brand marketing beats performance marketing, and defends the $1.5B acquisition of international rival Eucalyptus.
Dudum makes the case that avoiding hard conversations is the main failure mode of likeable founders, and describes how he forces discomfort into Hims' management practice as the company scaled.